Lista de obras -

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds.

artículo científico publicado en 2015

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer

artículo científico publicado en 2005

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response

artículo científico publicado en 2008

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration

artículo científico publicado en 2016

CHEK2 1100delC and male breast cancer in the Netherlands

artículo científico publicado en 2008

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

artículo científico publicado en 2016

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

artículo científico publicado en 2003

Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer

scientific article published on 03 May 2007

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients

artículo científico publicado en 2007

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

artículo científico publicado en 2008

Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers

artículo científico publicado en 2014

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

artículo científico publicado en 2002

Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.

artículo científico publicado en 2014

GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.

artículo científico publicado en 2016

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study

artículo científico publicado en 2007

How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study

artículo científico publicado en 2005

Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer

artículo científico publicado en 2009

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer

artículo científico publicado en 2010

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling

artículo científico publicado en 2005

Molecular profiling of platinum resistant ovarian cancer.

artículo científico publicado en 2006

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

artículo científico publicado en 2003

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

scientific article published on 01 January 2002

Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer

artículo científico publicado en 2006

Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer

artículo científico publicado en 2008

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

artículo científico publicado en 2003

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

artículo científico publicado en 2009

Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response

artículo científico publicado en 2010

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

artículo científico publicado en 2015

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer

artículo científico publicado en 2016

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients

scientific article published on 10 August 2011

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.

artículo científico publicado en 2016

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

artículo científico publicado en 2018

The prognostic value of BCAR1 in patients with primary breast cancer.

artículo científico publicado en 2004

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

artículo científico publicado en 2009

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer

artículo científico publicado en 2004

Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor

artículo científico publicado en 2007

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease

artículo científico publicado en 2004

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients

artículo científico publicado en 2006

Lista de obras de

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds.

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration

CHEK2 1100delC and male breast cancer in the Netherlands

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.

GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study

How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study

Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling

Molecular profiling of platinum resistant ovarian cancer.

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer

Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

The prognostic value of BCAR1 in patients with primary breast cancer.

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer

Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients